Back to Agenda
Benefit-Risk Evaluation in Drug Development
Session Chair(s)
Qi Jiang, PHD
Executive Director, Global Biostatistical Science, Amgen Inc., United States
This session will evaluate various potential systematic benefit-risk assessment approaches to cover the needs of global regulatory agencies and governance bodies, along with the application of the methods. This session was developed in conjunction with the Quantitative Sciences in Pharmaceutical Industry (QSPI) Benefit-Risk Working Group.
Learning Objective : Discuss the key existing benefit-risk methods; List recommended methods from statisticians in the Quantitative Sciences in Pharmaceutical Industry (QSPI) Benefit-Risk Working Group; Describe best practice sharing on benefit-risk assessment implementation.
Speaker(s)
George Quartey, PHD, MSC
Scientific Enablement Leader, Genentech, A Member of the Roche Group, United States
Structured Benefit-Risk Assessment Across the Life Cycle of Products: Methods, Examples and Challenges
Andreas Sashegyi, PHD
Senior Research Advisor, Statistics, Eli Lilly and Company, United States
Current Benefit-Risk Practice: What Has Resonated, What Has Not?
Qi Jiang, PHD
Executive Director, Global Biostatistical Science, Amgen Inc., United States
Uncertainty in Benefit-Risk Assessment
Have an account?